How do I read and understand my Cervical Cancer pathology report

Understanding Your Cervical Cancer Pathology Report

A pathology report is one of the most important documents in your cancer care—it describes what your tissue samples show under the microscope. Let me walk you through what to expect and what the key findings mean.

What IS a Pathology Report?

According to the NCCN Guidelines for Patients, a pathologist is a specialized doctor who examines tissue samples removed during a cervical biopsy. They look for abnormal areas, including cancer or pre-cancer, and determine the type of cervical cancer present. Your pathology report is their detailed findings.

Main Sections You'll See

1. SPECIMEN INFORMATION

This section identifies what was removed and tested:

• Type of sample: Cervical biopsy, cone biopsy (conization), or LEEP (Loop Electrosurgical Excision Procedure)
• Location: Whether tissue came from the ectocervix (outer part) or endocervix (canal)
• Date collected: When the sample was taken

Why it matters: The type and location of biopsy affects how your doctors interpret the findings.

---

2. HISTOLOGIC TYPE (The Kind of Cancer)

This is critical information. According to NCCN Guidelines, cervical cancer comes in three main types:

Squamous Cell Carcinoma (SCC)

• Most common type (~80-90% of cervical cancers)
• Starts in flat, scale-like cells on the outer cervix
• Usually HPV-associated (>90% of cases)

Adenocarcinoma

• Starts in mucus-producing glandular cells in the endocervical canal
• Less common than SCC
• Can be harder to detect early because it's in a harder-to-sample location

Adenosquamous Carcinoma

• Contains both squamous and glandular cancer cells
• Sometimes called "mixed" tumors
• Less common than the other two types

What to ask your doctor: "What type of cervical cancer do I have, and what does that mean for my treatment options?"

---

3. HPV STATUS (Human Papillomavirus Testing)

This is increasingly important. Your report should indicate:

• HPV-positive: The cancer is associated with HPV infection (most common)
• HPV-negative: The cancer developed without HPV (less common, about 5-7% of cases)

According to NCCN Guidelines, HPV status is determined through:

• HPV in-situ hybridization (ISH)
• Molecular testing
• p16 immunohistochemistry (IHC) staining—a special stain that shows HPV-associated changes

Why it matters: HPV status helps guide treatment decisions and may indicate different prognosis patterns.

What to ask your doctor: "Is my cancer HPV-positive or HPV-negative, and how does that affect my treatment?"

---

4. GRADE AND DEPTH OF INVASION

This describes how deep the cancer has grown into the cervix:

For early-stage disease (Stage IA):

• IA1: Invasion ≤3 mm deep
• IA2: Invasion >3 mm but ≤5 mm deep

For larger tumors (Stage IB and beyond):

• IB1: >5 mm deep, ≤2 cm in size
• IB2: >2 cm but ≤4 cm in size
• IB3: >4 cm in size

What to ask your doctor: "How deep has the cancer invaded, and what stage does that put me in?"

---

5. LYMPHOVASCULAR SPACE INVASION (LVSI)

This describes whether cancer cells have invaded into blood vessels or lymphatic vessels in the tissue.

• Present: Cancer cells found in vessels (may affect treatment decisions)
• Absent: No invasion into vessels (generally favorable)

Important note from NCCN Guidelines: LVSI doesn't officially change the FIGO stage, but some doctors consider it when planning treatment, especially for early-stage disease.

What to ask your doctor: "Does my report show LVSI, and how does that affect my treatment plan?"

---

6. MARGINS (For Cone or LEEP Biopsies)

If you had a cone biopsy or LEEP procedure, the report describes the edges of the removed tissue:

• Negative margins: No cancer cells at the edges (good sign—suggests complete removal)
• Positive margins: Cancer cells reach the edge (may need additional treatment)

What to ask your doctor: "Are my margins negative or positive, and what does that mean for my next steps?"

---

7. MOLECULAR TESTING & BIOMARKERS

According to the updated NCCN Guidelines, for advanced, metastatic, or recurrent cervical cancer, additional molecular testing may be performed to identify:

• HER2 amplification/overexpression: Associated with higher recurrence rates; may open targeted therapy options
• Mismatch repair (MMR) status or Microsatellite Instability (MSI)
• Tumor Mutational Burden (TMB)
• NTRK and RET gene fusions: Rare but important for targeted therapy options

Why it matters: These biomarkers help identify whether you might benefit from targeted therapies or immunotherapy, not just standard chemotherapy.

What to ask your doctor: "Have any molecular tests been done on my cancer? What do the results show?"

---

Questions to Ask Your Doctor About Your Pathology Report

1. What type of cervical cancer do I have? (SCC, adenocarcinoma, or adenosquamous?)

2. Is my cancer HPV-positive or HPV-negative?

3. How deep has the cancer invaded into the cervix?

4. What is my FIGO stage based on these findings?

5. Does my report show LVSI, and how does that affect treatment?

6. If I had a cone or LEEP biopsy, are my margins negative or positive?

7. Have any molecular tests been performed (HER2, MMR/MSI, TMB, NTRK, RET)?

8. Based on these pathology findings, what are my treatment options?

9. Do you recommend any additional testing before we plan treatment?

10. Can you explain what any unfamiliar terms in my report mean?

---

Key Takeaway

Your pathology report is the foundation for your treatment plan. According to NCCN Guidelines, the pathologic findings—including tumor type, depth of invasion, HPV status, and molecular markers—directly determine which treatment approaches your doctors will recommend.

Don't hesitate to ask your healthcare team to explain any part of your report. Understanding your diagnosis helps you participate in shared decision-making about your care.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.